Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study

Bibliographic Details
Title: Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study
Authors: Motomu Hashimoto, Moritoshi Furu, Wararu Yamamoto, Takanori Fujimura, Ryota Hara, Masaki Katayama, Akira Ohnishi, Kengo Akashi, Shuzo Yoshida, Koji Nagai, Yonsu Son, Hideki Amuro, Toru Hirano, Kosuke Ebina, Ryuji Uozumi, Hiromu Ito, Masao Tanaka, Koichiro Ohmura, Takao Fujii, Tsuneyo Mimori
Source: Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-10 (2018)
Publisher Information: BMC, 2018.
Publication Year: 2018
Collection: LCC:Diseases of the musculoskeletal system
Subject Terms: Rheumatoid arthritis, Biological disease-modifying antirheumatic drugs, Discontinuation, Tumor necrosis factor, Diseases of the musculoskeletal system, RC925-935
More Details: Abstract Background Clinical remission can be maintained after the discontinuation of biological disease-modifying antirheumatic drugs (bDMARDs) in some patients with rheumatoid arthritis (RA) (bDMARD-free remission (BFR)). It is unknown which bDMARD is advantageous for achieving BFR or under which conditions BFR can be considered. This study aimed to determine the factors associated with BFR achievement in clinical practice. Methods Patients with RA were enrolled from a Japanese multicenter observational registry. Patients with RA who achieved clinical remission (Disease Activity Score 28—C-reactive protein 6 months), Boolean remission, no glucocorticoid use at the time of bDMARD discontinuation, and use of TNFi(mAb) or CTLA4-Ig remained as independent factors associated with BFR. Conclusions BFR can be achieved in some patients with RA after bDMARD discontinuation in clinical practice. Use of TNFi(mAb) or CTLA4-Ig, sustained remission, Boolean remission, and no glucocorticoid use at the time of bDMARD discontinuation are advantageous for achieving BFR.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1478-6362
Relation: http://link.springer.com/article/10.1186/s13075-018-1673-1; https://doaj.org/toc/1478-6362
DOI: 10.1186/s13075-018-1673-1
Access URL: https://doaj.org/article/4cd5e2f3433e4dbcad326af2ee7761ea
Accession Number: edsdoj.4cd5e2f3433e4dbcad326af2ee7761ea
Database: Directory of Open Access Journals
More Details
ISSN:14786362
DOI:10.1186/s13075-018-1673-1
Published in:Arthritis Research & Therapy
Language:English